Matthew Fomonyuy Yuyun, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenomedullin | 2 | 2017 | 85 | 1.110 |
Why?
|
| Albuminuria | 6 | 2005 | 667 | 1.090 |
Why?
|
| Arrhythmias, Cardiac | 6 | 2023 | 2220 | 0.940 |
Why?
|
| Bradycardia | 3 | 2020 | 290 | 0.870 |
Why?
|
| Atrioventricular Block | 2 | 2018 | 110 | 0.720 |
Why?
|
| Defibrillators, Implantable | 4 | 2021 | 1429 | 0.710 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2021 | 501 | 0.660 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2022 | 1511 | 0.660 |
Why?
|
| Sick Sinus Syndrome | 1 | 2018 | 42 | 0.650 |
Why?
|
| Biopterin | 1 | 2018 | 65 | 0.640 |
Why?
|
| Tetrahydrofolates | 1 | 2018 | 61 | 0.640 |
Why?
|
| Electric Countershock | 1 | 2021 | 520 | 0.630 |
Why?
|
| Heart Failure | 6 | 2022 | 10378 | 0.590 |
Why?
|
| Device Removal | 1 | 2021 | 650 | 0.540 |
Why?
|
| Atrial Fibrillation | 4 | 2023 | 4827 | 0.500 |
Why?
|
| Primary Dysautonomias | 2 | 2022 | 25 | 0.450 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 14701 | 0.430 |
Why?
|
| Nitric Oxide | 1 | 2018 | 2101 | 0.350 |
Why?
|
| Africa South of the Sahara | 3 | 2020 | 706 | 0.340 |
Why?
|
| Hemodynamics | 1 | 2018 | 4217 | 0.310 |
Why?
|
| Myocardial Infarction | 4 | 2017 | 11531 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2022 | 11403 | 0.290 |
Why?
|
| Retinal Diseases | 2 | 2022 | 666 | 0.280 |
Why?
|
| Catheter Ablation | 2 | 2023 | 2696 | 0.270 |
Why?
|
| Hypoglycemia | 2 | 2022 | 835 | 0.270 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 4512 | 0.270 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2020 | 848 | 0.260 |
Why?
|
| Stroke Volume | 3 | 2022 | 4753 | 0.260 |
Why?
|
| Morbidity | 2 | 2020 | 1729 | 0.250 |
Why?
|
| Genital Diseases, Male | 1 | 2004 | 83 | 0.240 |
Why?
|
| Incidence | 7 | 2022 | 20743 | 0.170 |
Why?
|
| Diabetic Neuropathies | 1 | 2003 | 407 | 0.170 |
Why?
|
| Risk Factors | 15 | 2022 | 70971 | 0.170 |
Why?
|
| Cardiology | 2 | 2020 | 1627 | 0.170 |
Why?
|
| Ventricular Function, Left | 2 | 2021 | 3498 | 0.170 |
Why?
|
| Urinary Tract Infections | 1 | 2004 | 745 | 0.160 |
Why?
|
| Long QT Syndrome | 1 | 2022 | 441 | 0.160 |
Why?
|
| Developed Countries | 1 | 2020 | 421 | 0.150 |
Why?
|
| Education | 1 | 2020 | 548 | 0.150 |
Why?
|
| Minority Groups | 2 | 2020 | 1133 | 0.150 |
Why?
|
| Humans | 36 | 2023 | 725001 | 0.140 |
Why?
|
| Heart Rate | 3 | 2022 | 4068 | 0.140 |
Why?
|
| Atrial Flutter | 1 | 2018 | 252 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2018 | 698 | 0.130 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 967 | 0.130 |
Why?
|
| Homocysteine | 1 | 2018 | 642 | 0.130 |
Why?
|
| Middle Aged | 21 | 2022 | 212155 | 0.130 |
Why?
|
| Survival Rate | 3 | 2020 | 12795 | 0.120 |
Why?
|
| Action Potentials | 1 | 2021 | 1795 | 0.120 |
Why?
|
| Cause of Death | 1 | 2004 | 3557 | 0.110 |
Why?
|
| Autonomic Nervous System | 3 | 2022 | 671 | 0.110 |
Why?
|
| Electric Power Supplies | 1 | 2013 | 98 | 0.110 |
Why?
|
| Stroke | 3 | 2022 | 9569 | 0.110 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 796 | 0.110 |
Why?
|
| Electrocardiography | 4 | 2022 | 6404 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2020 | 1153 | 0.110 |
Why?
|
| Lyme Disease | 1 | 2018 | 601 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 14955 | 0.100 |
Why?
|
| Folic Acid | 1 | 2018 | 1289 | 0.100 |
Why?
|
| Aged | 13 | 2021 | 161379 | 0.100 |
Why?
|
| Income | 1 | 2020 | 1830 | 0.100 |
Why?
|
| England | 3 | 2014 | 521 | 0.100 |
Why?
|
| Male | 21 | 2022 | 346964 | 0.100 |
Why?
|
| Prognosis | 5 | 2017 | 28718 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 6527 | 0.090 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2021 | 1396 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 12318 | 0.090 |
Why?
|
| Veterans | 1 | 2023 | 2347 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 12244 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2023 | 61674 | 0.090 |
Why?
|
| Female | 21 | 2022 | 375303 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2022 | 2761 | 0.090 |
Why?
|
| Coronary Disease | 1 | 2004 | 6082 | 0.080 |
Why?
|
| Age Distribution | 2 | 2004 | 2903 | 0.080 |
Why?
|
| Adult | 16 | 2022 | 211523 | 0.070 |
Why?
|
| Time Factors | 3 | 2018 | 40178 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2018 | 3094 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 936 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2018 | 1738 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2014 | 1797 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2021 | 8464 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2021 | 23178 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2018 | 3227 | 0.070 |
Why?
|
| Heart | 3 | 2022 | 4367 | 0.060 |
Why?
|
| Cameroon | 1 | 2004 | 70 | 0.060 |
Why?
|
| Heart Arrest | 1 | 2014 | 1412 | 0.060 |
Why?
|
| Urethral Stricture | 1 | 2004 | 48 | 0.060 |
Why?
|
| Registries | 1 | 2020 | 7910 | 0.060 |
Why?
|
| Prevalence | 3 | 2004 | 14951 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 6196 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2022 | 51853 | 0.050 |
Why?
|
| Morocco | 1 | 2020 | 28 | 0.050 |
Why?
|
| Africa, Northern | 1 | 2020 | 81 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2013 | 5894 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2023 | 1313 | 0.050 |
Why?
|
| Prostatic Hyperplasia | 1 | 2004 | 525 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2004 | 2304 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 654 | 0.040 |
Why?
|
| Cardiology Service, Hospital | 1 | 2020 | 248 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2004 | 785 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2022 | 39883 | 0.040 |
Why?
|
| Capacity Building | 1 | 2020 | 246 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2005 | 1352 | 0.040 |
Why?
|
| Recurrence | 2 | 2023 | 8216 | 0.040 |
Why?
|
| Ceftriaxone | 1 | 2018 | 156 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2023 | 74145 | 0.040 |
Why?
|
| Temperature | 1 | 2023 | 2213 | 0.040 |
Why?
|
| Doxycycline | 1 | 2018 | 317 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 17328 | 0.030 |
Why?
|
| HIV Infections | 1 | 2021 | 16214 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 57615 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2004 | 1337 | 0.030 |
Why?
|
| Hypertension | 2 | 2005 | 8250 | 0.030 |
Why?
|
| South Africa | 1 | 2020 | 1648 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 23445 | 0.030 |
Why?
|
| Wales | 1 | 2014 | 85 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 38720 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 5342 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2004 | 6881 | 0.030 |
Why?
|
| Mass Screening | 2 | 2006 | 5198 | 0.030 |
Why?
|
| Medical Audit | 1 | 2014 | 469 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 1403 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2020 | 3907 | 0.030 |
Why?
|
| Developing Countries | 1 | 2004 | 2735 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2004 | 9837 | 0.030 |
Why?
|
| Ventricular Fibrillation | 1 | 2014 | 539 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15004 | 0.020 |
Why?
|
| Animals | 1 | 2022 | 168735 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 2766 | 0.020 |
Why?
|
| Exercise Test | 1 | 2018 | 2049 | 0.020 |
Why?
|
| Sex Factors | 1 | 2004 | 10385 | 0.020 |
Why?
|
| Logistic Models | 1 | 2004 | 13356 | 0.020 |
Why?
|
| Calcium | 1 | 2021 | 5758 | 0.020 |
Why?
|
| Smoking | 1 | 2004 | 8882 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 3510 | 0.020 |
Why?
|
| Age Factors | 1 | 2004 | 18337 | 0.020 |
Why?
|
| Patient Admission | 1 | 2014 | 1368 | 0.020 |
Why?
|
| Echocardiography | 1 | 2018 | 5061 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2020 | 4421 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 4234 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 24043 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 12937 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 10879 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2014 | 10244 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2006 | 1297 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2014 | 5222 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2014 | 3048 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 6995 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 14713 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2004 | 1660 | 0.010 |
Why?
|
| ROC Curve | 1 | 2004 | 3491 | 0.010 |
Why?
|
| Adolescent | 1 | 2004 | 84411 | 0.010 |
Why?
|
| Neoplasms | 1 | 2004 | 20947 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2006 | 3579 | 0.010 |
Why?
|
| Health Surveys | 1 | 2004 | 4002 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2004 | 6212 | 0.010 |
Why?
|